中国普通外科杂志 ›› 2021, Vol. 30 ›› Issue (3): 254-260.doi: 10.7659/j.issn.1005-6947.2021.03.002

• 专题研究 • 上一篇    下一篇

血清ANGPTL2与胰腺癌临床病理特征的关系及其在胰腺癌诊断中的价值

秦雯1,陈泰文2,郑海平3,杨建宇1,朱小东4   

  1. (广西医科大学附属武鸣医院  1. 病理科  4. 肿瘤科,广西 南宁 530199;2. 广西医科大学附属肿瘤医院 胃及腹部肿瘤病区,广西 南宁 530021;3. 广西医科大学第一附属医院  肿瘤内科,广西 南宁 530021)
  • 收稿日期:2021-01-20 修回日期:2021-02-25 出版日期:2021-03-25 发布日期:2021-04-06
  • 通讯作者: 郑海平, Email: zhenghaiping@163.com
  • 作者简介:秦雯,广西医科大学附属武鸣医院副主任医师,主要从事肿瘤分子病理学相关方面的研究。
  • 基金资助:
    国家自然科学基金资助项目(81860508);广西自然科学基金资助项目(2018GXNSFAA138026);广西壮族自治区卫生和计划生育委员会基金资助项目(Z20180950);广西南宁市武鸣区科学研究与技术开发计划资助项目(20190403);广西医疗卫生适宜技术开发与推广应用基金资助项目(S2018040)。

Association of serum ANGPTL2 with clinicopathologic features of pancreatic cancer and its diagnostic value for pancreatic cancer

QIN Wen1, CHEN Taiwen2, ZHENG Haiping3, YANG Jianyu1, ZHU Xiaodong4    

  1. (1. Department of Pathology 4. Department of Oncology, Wuming Hospital of Guangxi Medical University, Nanning 530199, China; 2. Division of Gastric and Abdominal Oncology, Guangxi Medical University Cancer Hospital, Nanning 530021, China; 3. Department of Oncology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China)
  • Received:2021-01-20 Revised:2021-02-25 Online:2021-03-25 Published:2021-04-06

摘要: 背景与目的:胰腺癌临床起病隐匿,患者确诊时大多数已属晚期,失去了根治性治疗的机会。因此,寻找一种新的生物标志物用于胰腺癌的诊断具有重要意义。本研究探讨胰腺癌患者血清血管生成素样蛋白2(ANGPTL2)与病理特征的关系及其在胰腺癌诊断中的价值。
方法:比较125例胰腺癌患者和66例健康体检者血清ANGPTL2水平;用统计学方法分析胰腺癌患者血清ANGPTL2水平高低与临床病理参数、CA19-9水平的关系以及胰腺癌的危险因素;采用ROC曲线分析血清ANGPTL2、血清CA19-9以及两者联合检测对胰腺癌的诊断效能。
结果:胰腺癌患者血清平均ANGPTL2水平明显高于健康人群(6.52 ng/mL vs. 3.78 ng/mL,P<0.05);胰腺癌患者血清ANGPTL2水平与肿瘤的大小、组织学分级、淋巴结转移和TNM分期密切有关(均P<0.05),而与性别、年龄、远处转移无关(均P>0.05);血清ANGPTL2水平与CA19-9水平呈明显正相关(r=0.772,P<0.001);单因素分析和多因素分析显示,糖尿病(P=0.016)和ANGPTL2(P=0.014)是引起胰腺癌的独立危险因素;血清ANGPTL2、CA19-9及两者联合检测对胰腺癌诊断的AUC分别为0.939、0.953、0.966,特异度与阳性预测值分别为92.4%与95.7%、84.8%与91.9%、98.5%与96.4%。
结论:胰腺癌患者血清ANGPTL2水平升高,其表达与临床病理特征密切相关;ANGPTL2与CA19-9联合检测对胰腺癌的诊断具有一定价值。

关键词: 胰腺肿瘤, 血管生成素样蛋白质类, 血清学试验, 生物标记, 肿瘤

Abstract: Background and Aims: The onset of pancreatic cancer is insidious and most of the patients were diagnosed at an advanced stage, thus losing the chance of radical treatment. Therefore, finding a new biomarker for the diagnosis of pancreatic cancer is of great significance. This study was conducted to investigate the association of the serum angiopoietin-like protein 2 (ANGPTL2) in pancreatic cancer patients with the clinicopathologic characteristics and its application value in diagnosis of pancreatic cancer. 
Methods: Serum ANGPTL2 levels between 125 pancreatic cancer patients and 66 healthy subjects were compared. The relations of serum ANGPTL2 level with the clinicopathologic variables and CA19-9 level as well as the risk factors for pancreatic cancer were analyzed by statistical methods. ROC curve was used to analyze the diagnostic abilities of serum ANGPTL2, serum CA19-9 and their combined detection for pancreatic cancer.
Results: The average serum level of ANGPTL2 in pancreatic cancer patients was significantly higher than that in healthy individuals (6.52 ng/mL vs. 3.78 ng/mL, P<0.05). The serum ANGPTL2 level in pancreatic cancer patients was significantly related to tumor size, histological grade, lymph node metastasis and TNM stage (all P<0.05), and irrelevant to sex, age and distant metastasis (all P>0.05). There was a significant positive correlation between serum ANGPTL2 level and CA19-9 level (r=0.772, P<0.001). Univariate and multivariate analysis showed that diabetes mellitus (P=0.016) and ANGPTL2 (P=0.014) were independent risk factors for pancreatic cancer. The AUC values of serum ANGPTL2, CA19-9 and their combined detection for diagnosis of pancreatic cancer were 0.939, 0.953 and 0.966, with the specificity/positive predictive value of 92.4%/95.7%, 84.8%/91.9%, and 98.5%/96.4%.
Conclusion: Serum ANGPTL2 level is elevated in pancreatic cancer patients. The ANGPTL2 level is closely related to the clinicopathologic features. The combined detection of ANGPTL2 and CA19-9 has certain value in diagnosis of pancreatic cancer.

Key words: Pancreatic Neoplasms, Angiopoietin-like Proteins, Serologic Tests, Biomarkers, Tumor

中图分类号: 

  • R735.9
[1] 韩仕锋, 金春风, 朱磊. 预后指数在可切除胰腺导管腺癌患者术后评估中临床价值[J]. 中国普通外科杂志, 2021, 30(3): 247-253.
[2] 刘向梅, 许达峰, 王春玲, 符于正, 王丹, 武金才. NIMA相关激酶2在胰腺癌中的表达及其临床意义[J]. 中国普通外科杂志, 2021, 30(3): 269-275.
[3] 李铭旭, 仲成成, 张功铭, 胡伟, , 王仲, . DEP结构域蛋白质1B在胰腺癌中的表达及其临床意义[J]. 中国普通外科杂志, 2021, 30(3): 261-268.
[4] 张波, 徐涛, 徐浩, 夏雨, 周文策, . 基于生物信息学胰腺腺癌关键基因的筛选及支持向量机诊断模型的构建[J]. 中国普通外科杂志, 2021, 30(3): 276-285..
[5] 李威威, 刘金龙. 循环肿瘤DNA在胰腺癌中的临床应用进展[J]. 中国普通外科杂志, 2021, 30(3): 337-342.
[6] 谢学文, 费书珂. 中性粒细胞胞外诱捕网与胰腺疾病的研究进展[J]. 中国普通外科杂志, 2021, 30(3): 343-348.
[7] 周艳, 陈超, 杨竹林, 熊力. 长链非编码RNA在肝细胞性肝癌中的作用[J]. 中国普通外科杂志, 2021, 30(3): 349-356.
[8] 王蒲雄志, 于新哲, 史向军, 袁周 . 胰腺导管腺癌的免疫治疗研究进展 [J]. 中国普通外科杂志, 2021, 30(3): 330-336.
[9] 牛恒, 杨昆宪. 免疫微生态肠内营养联合加速康复策略对结直肠癌患者术后免疫状态的影响[J]. 中国普通外科杂志, 2021, 30(3): 369-374.
[10] 卓恩挺, 王连臣, 符国宏, 潘建民. 腹腔镜下腹会阴直肠癌手术中腹膜外造口与腹膜内造口的疗效比较[J]. 中国普通外科杂志, 2021, 30(2): 241-246.
[11] 韩伟光, 莘玮, 苏水霞, 王青. 基于生物信息学的胆囊癌差异表达谱中关键蛋白调控基因分析[J]. 中国普通外科杂志, 2021, 30(2): 165-172.
[12] 周京涛, 刘佳, 努尔买买提·阿米都拉, 闫军, 寇旭东, 张鸽文. 上调lncRNA SNHG12与miR-199a-5p/FZD6轴对肝细胞癌细胞增殖、侵袭和上皮-间质转化的影响[J]. 中国普通外科杂志, 2021, 30(2): 173-186.
[13] 刘继升, 刘河, 刘浩, YU Xing, 李浩. TIP30在肝内胆管癌中的表达及意义[J]. 中国普通外科杂志, 2021, 30(2): 187-194.
[14] 陈伟钊, 吴嘉艺, 黄晓晓, 吕嘉晖, 黄理铭, 严茂林 . “q”形胆管切开取栓术在肝细胞癌伴B4型胆管癌栓治疗中的应用价值[J]. 中国普通外科杂志, 2021, 30(2): 151-157.
[15] 张帆, 李泽东, 彭禹, 陈胜, 周钧. 基于血清miRNA表达数据的胰腺癌诊断决策树构建[J]. 中国普通外科杂志, 2021, 30(2): 211-218.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 龚丽, 欧阳文, 裴琛琳, 陈志康, 朱红, 董超, . 妊娠合并BRAF突变晚期结肠癌国际会诊病例诊治体会并文献复习[J]. 中国普通外科杂志, 2020, 29(4): 510 -514 .
[2] 赵文娟, 朱燕梅, 李晓玲, 秦洁 . 基于微信平台的围手术期干预在乳腺癌全程个案管理中的应用[J]. 中国普通外科杂志, 2020, 29(5): 630 -634 .
[3] 肖卫星,周君,顾梦佳,肖广远. 精准肝切除在肝内胆管结石手术治疗中的应用[J]. 中国普通外科杂志, 2016, 25(2): 191 -196 .
[4] 杨艳婷, 鲁明典, 夏俊, 郑慧, 童清平, 毛萍 . 腔内超声与高分辨薄层直肠MRI新序列在术前评估与直肠癌术后病理结果的对比分析[J]. 中国普通外科杂志, 2020, 29(4): 498 -503 .
[5] 白宁1, 2|王栋2|欧阳锡武2|周乐杜2|王志明2. 苦参碱对大鼠肝缺血再灌注损伤的抑制作用及机制[J]. , 2018, 27(1): 81 -86 .
[6] 肖润沙, 唐文彬, 陈子华, 成小苗. 胃肠道肿瘤合并肾损害30例报告并文献复习[J]. 中国普通外科杂志, 2020, 29(4): 504 -509 .
[7] 黄隽, 胡元萍, 陈创, 齐晓伟. 新型冠状病毒肺炎疫情特殊时期对乳腺癌治疗临床问题的若干思考[J]. 中国普通外科杂志, 2020, 29(2): 153 -160 .
[8] 廖信芳1,李正荣2,杨清水1,张乡城2, 李柱1,揭志刚2. microRNA-139-5p及其靶基因Notch1在结直肠癌中的作用[J]. 中国普通外科杂志, 0, (): 1373 -1378 .
[9] 项灿宏|童翾 . 肝门部胆管癌外科治疗的进展与争议[J]. , 2018, 27(2): 137 -142 .
[10] 黄耿文|申鼎成|何文|杨柳|周书毅|阳建怡|纪连栋|魏伟. 快速康复模式下的腹腔镜腹股沟疝修补术[J]. , 2016, 25(10): 1470 -1474 .